Investors Buy Gilead Sciences (GILD) on Weakness

Investors bought shares of Gilead Sciences (NASDAQ:GILD) on weakness during trading hours on Monday. $76.45 million flowed into the stock on the tick-up and $56.15 million flowed out of the stock on the tick-down, for a money net flow of $20.30 million into the stock. Of all companies tracked, Gilead Sciences had the 19th highest net in-flow for the day. Gilead Sciences traded down ($0.39) for the day and closed at $67.63

Several research analysts have weighed in on GILD shares. Leerink Swann reaffirmed a “market perform” rating and set a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Thursday, April 19th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Barclays lowered their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 2nd. Finally, Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. One analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $88.14.

The firm has a market cap of $87.94 billion, a price-to-earnings ratio of 7.93, a P/E/G ratio of -5.88 and a beta of 1.19. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). The firm had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm’s revenue was down 21.8% compared to the same quarter last year. During the same period last year, the business earned $2.23 EPS. research analysts predict that Gilead Sciences will post 5.75 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be issued a $0.57 dividend. The ex-dividend date is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.36%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In related news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $78.65, for a total transaction of $3,932,500.00. Following the completion of the sale, the chairman now directly owns 3,067,762 shares in the company, valued at approximately $241,279,481.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 226,667 shares of company stock worth $17,060,854. 1.16% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of GILD. Amalgamated Bank raised its holdings in Gilead Sciences by 7.5% during the first quarter. Amalgamated Bank now owns 182,599 shares of the biopharmaceutical company’s stock worth $13,766,000 after purchasing an additional 12,802 shares in the last quarter. Summit Trail Advisors LLC raised its holdings in Gilead Sciences by 40.9% during the first quarter. Summit Trail Advisors LLC now owns 7,808 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 2,265 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Gilead Sciences by 5.3% during the first quarter. Principal Financial Group Inc. now owns 2,945,595 shares of the biopharmaceutical company’s stock worth $222,068,000 after purchasing an additional 148,398 shares in the last quarter. WINTON GROUP Ltd raised its holdings in Gilead Sciences by 16.4% during the first quarter. WINTON GROUP Ltd now owns 7,674 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 1,079 shares in the last quarter. Finally, Cypress Capital Group raised its holdings in Gilead Sciences by 6.4% during the first quarter. Cypress Capital Group now owns 43,799 shares of the biopharmaceutical company’s stock worth $3,302,000 after purchasing an additional 2,621 shares in the last quarter. 77.72% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply